1st Quarter - Report

CROSSROADS STRATEGIES, LLC for MERCK & CO., INC.

Firm
Client
Income
$40,000
Expenses
—

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Trade (domestic/foreign) TRD

Issues related to pharmaceutical IP, supply chain, and tariffs; Section 232 tariff investigation on branded pharmaceuticals.

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Copyright/Patent/Trademark CPT

Biopharmaceutical innovation and patent policy issues. Bayh-Dole march-in rights policy issues.

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Health Issues HCR

Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program (FY2027 National Defense Authorization Act), antimicrobial resistance, VICP Program, PBM reform, vaccine schedule and vaccine safety; Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 891 (119th)

Medicare/Medicaid MMM

General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; CMMI Drug Pricing Demonstration Programs; Drug Pricing; Inflation Reduction Act of 2022 (P.L.117-169) implementation.

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Taxation/Internal Revenue Code TAX

Issues related to tax reform; R&D tax credit; international taxation; H.R.1, One Big Beautiful Bill Act (P.L.119-21) implementation.

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 1 (119th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.